Pulmonx Completes Enrollment of Randomized, Prospective, Multi-Center Study in New Patient Population
Pulmonx®, a leader in interventional pulmonology, today announced completion of enrollment in the IMPACT study, a prospective, randomized, multi-center study that is the first to examine the benefits of the Zephyr® Endobronchial Valve (EBV) specifically in patients with homogeneous emphysema.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160114005415/en/
The Zephyr Endobronchial Valve by Pulmonx. Image courtesy of Pulmonx Corporation.
The IMPACT study enrolled 93 patients with homogeneous severe emphysema to compare the safety and effectiveness of Zephyr EBV treatment versus medical management. The study is being led by Associate Professor Arschang Valipour, MD, FCCP, of the Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology at Otto-Wagner-Spital in Vienna, Austria, and Professor Ralf Eberhardt, MD, of Thoraxklinik, University of Heidelberg (Co-principal investigators), and conducted at leading medical centers in Austria, Germany and the Netherlands.
It was previously thought that only patients with heterogeneous emphysema, where the disease is isolated to specific areas of the lungs, could benefit from lung volume reduction with endobronchial valves. The IMPACT study was launched based on the promising results of a retrospective analysis of the VENT trial, which indicated that patients with homogeneous disease, where emphysema is diffusely distributed, and little or no collateral ventilation can also benefit from endobronchial lung volume reduction with the Zephyr valve.1
The study uses the company’s proprietary Chartis® System to select patients with little or no collateral ventilation, and advanced imaging technology to select a target lobe for treatment. The use of the Chartis System to select patients for EBV treatment was validated in the STELVIO trial, which was recently published in the New England Journal of Medicine.2 Results of the STELVIO trial showed that at six months, patients selected with the Chartis System and treated with the Zephyr EBV had statistically and clinically greater improvements in pulmonary function, exercise capacity and quality of life compared to patients managed medically. Importantly, STELVIO included patients with both heterogeneous and homogeneous emphysema, and both populations treated with the Zephyr EBV had statistically greater and clinically meaningful outcomes than medically managed patients. The full text of the NEJM article can be accessed here.
“An ever-growing body of evidence supports the benefits of the Zephyr EBV in improving lung function and quality of life for patients,” said Dr. Arschang Valipour, co-principal investigator for the IMPACT study. “Retrospective studies have demonstrated the benefits of the EBV in patients with homogeneous emphysema. The IMPACT study is breaking new ground by prospectively evaluating the benefits of EBV treatment specifically in this homogeneous emphysema patient population, who clearly need additional treatment options.”
“Zephyr valves offer the greatest level of improvement of any minimally invasive procedure for emphysema, and valves are the only removable option,” said Pulmonx Chief Executive Officer Glen French. “Completing enrollment in the IMPACT study is an important milestone as we accumulate scientific evidence for the patient populations that can benefit the most from our treatment.”
Three randomized controlled trials of the Zephyr EBV (STELVIO, BeLieVeR-HIFi, VENT) conducted to date provide a significant body of evidence supporting the therapy. These and other studies have demonstrated significant improvements in lung function, exercise capacity and quality of life in patients who are treated with the Zephyr EBV, with greater benefit in patients with low collateral ventilation2,3,4,5. The clinical data also demonstrate sustained patient benefits out to five years.6
The Zephyr EBV is currently being studied in the United States as part of the pivotal LIBERATE trial. Interested patients can determine if they are a candidate by visiting https://pulmonx.com/us/liberate-endobronchial-valve-study/liberate-screener/ or by calling (888) 248-LUNG (888-248-5864).
The Zephyr EBV is a tiny, one-way valve placed in the lungs to block airflow to diseased regions in order to achieve lung volume reduction. The Chartis System is a proprietary diagnostic utilized immediately prior to the Zephyr EBV procedure to identify those patients with low or no collateral ventilation, who are the most likely to respond to the treatment. More than 65 percent of severe emphysema patients have been shown to have low or no collateral ventilation in one or more target lobes of the lung, demonstrating a large potential market for the Zephyr EBV treatment. Zephyr EBVs have been implanted globally in more than 10,000 patients. To view a video of the Zephyr EBV procedure, click here.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.
The Zephyr EBV is an investigational device in the United States. Limited by U.S. law to investigational use only.
- Herth FJ, Gompelmann D, Criner GJ, Sciurba FC, Ernst A, Eberhardt R. Lung Volume Reduction Using Endobronchial Valves in COPD Patients with Low Emphysema Heterogeneity Scores. Am J Respir Crit Care Med 191;2015: A1156.
- Klooster K, Ten Hacken NHT, Hartman JE, Kerstjens HAM, Van Rikxoort EM, Slebos DJ. Endobronchial Valves for emphysema without interlobar collateral ventilation. N Engl J Med 2015; 373:2325-2335.
- Davey C, Zoumot Z, Jordan S, McNulty W, Carr D, Hind M, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. The Lancet 2015; http://dx.doi.org/10.1016/S0140-6736(15)60001-0 (including supplementary appendix). [Epub ahead of print]
- Sciurba FC, Ernst A, Herth FJF, Strange C, Criner G, Marquette C, et al. A Randomized Study of Endobronchial Valves for Advanced Emphysema. New Eng J Med 2010; 363: 1233-1244 (including supplementary appendix).
- Herth F, Noppen M, Valipour A, Leroy S, Vergnon J-M, Ficker JH, Egan E, Gasparini S, Agusti C, Homes-Higgin D, Ernst A on behalf of the International VENT Study Group. Efficacy predictors of endoscopic lung volume reduction with Zephyr valves in a European cohort with emphysema. Eur Respir J 2012; 39: 1334-1342.
- Venuta F, A Marco, D Daniele, Coloni, G, et. al. Long-term follow-up after bronchoscopic lung volume reduction in patients with emphysema. Eur Respir J 2012; 39: 1084–1089.
(949) 545-6654 or (310) 902-1274
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00 | Pressemelding
Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom